Abstracts tagged "ankylosing spondylitis (AS) and comparative effectiveness and harms"

Abstract Number: 2251 • ACR/ARHP Annual Meeting 2016

Secukinumab Vs Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis at 52 Weeks from the US Perspective

Jessica Walsh¹, Efthalia Nikoglou², Gunda Praveen³, Yujin Park⁴ and Steffen Jugl⁵, ¹University of Utah School of Medicine, Salt Lake City, UT, ²Novartis Ireland, Ltd, Dublin, Ireland, ³Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland